

CURRICULUM VITAE

PHILIP DAVID KELL

May 2008

CONTENTS:

PERSONAL DETAILS	Page 3
PUBLICATIONS	Page 4-14
MANAGEMENT	Page 15
TEACHING	Page 16
SEXUAL DYSFUNCTION EXPERIENCE	Page 17

PERSONAL DETAILS

DATE OF BIRTH: 02 12 1954

ADDRESS: 145 Harley Street, London, W1G 6BJ

TELEPHONE: 020 7486 3840

PRESENT POSITION:

Consultant Physician, Maidstone and Tunbridge Wells NHS Trust

Consultant Physician, Institute of Urology, Middlesex Hospital, Mortimer Street, London
W1T, 3AA Phone

Consultant Physician, Hospital of St Johns and St Elizabeths 60 Grove End Rd St
Johns Wood London NW8

Consultant Physician, The London Clinic, 145 Harley St, W1G 6BJ

EMPLOYER: MTW NHS Trust

QUALIFICATIONS:

MB BS (SYDNEY) 1979, Dip. Obst. RACOG 1983, Dip. GUM (LSA) 1991, MFFP
(RCOG) 1994, PCM (OU) 1995, PDM (OU) 1996, FACSHP 1999, MBA (OU) 2001,
MSc (UCL) 2001, FRCOG 2002, FRCP(I) 2004.

PUBLICATIONS

A. PAPERS

1. O'Donovan D, Kell P. Malignant granular cell tumour with intraperitoneal dissemination. *Histopathology* 1989 14;4:417-9.
2. Kell P, Barton S, Hawkins D, Marwood R, Howard L. The clinical presentation of women with human immunodeficiency virus infection. *Br J Obstet Gynaecol* 1991;98:103-4.
3. Kell P, Barton S, Summerbell C, Lawrence A. Sexually transmitted diseases in HIV-1 seropositive women at presentation. *Int J STD & AIDS* 1991;2:204-6.
4. Kell P, Barton S. How do women with HIV infection present ? Editorial in *Mat Child Health* 1991;11:340-4.
5. Kell P, Barton S, Smith D, Nelson M, Marwood R, Gazzard B. A maternal death caused by AIDS. *Br J Obstet Gynaecol* 1991;98:725-7.
6. Kell P, Barton S, Smith D, Migley L, Samarasinghe P, Gazzard B. Disseminated histoplasmosis in an AIDS patient successfully treated with Itraconazole. *Genitourin Med* 1991;67:342-344.
7. Kell P. Reasons why people refuse HIV tests. *Nurs Stand* 1991 5;29:16
8. Kell P, Barton S, Boag F. Incorporating patients' views in planning services for women with HIV infection. *Genitourin Med* 1992;68:233-4.
9. Kell P, Barton S, Edmonds K, Boag F. HIV infection in a patient with Meyer-Rokitansky-Kuster-Hauser syndrome. *J R Soc Med* 1992;85:706-7.
10. Daniels D, Kell P, Nelson M, Barton S. Sexual behaviour amongst travellers: A study of Genito-urinary Medicine clinic attenders. *Int J STD & AIDS* 1992;3:437-8.
11. McCarthy G, Cockell A, Kell P, Beevor A, Boag F. A women only clinic for HIV, genito-urinary medicine and substance misuse. *Genitourin Med* 1992;68:386-90.

12. Shah P, Kell P, Barton S. Editorial: Gynaecological disorders and HIV infection. *Int J STD & AIDS* 1994;5:383-6.
13. Brook M, Kell P, Atia W. Accuracy of computerized diagnostic records for chlamydia, syphilis, gonorrhoea and herpes. *Int J STD & AIDS* 1995;6:60.
14. Brook M, Clark S, Stirland A, Kelsey M, Paice E, Kell P, Atia W. A case cluster of possible tissue invasive gonorrhoea. *Genitourin Med* 1995;71:126-8.
15. Evans B, McCormack S, Kell P, Bond R, MacRae K. Trends in female sexual behaviour and sexually transmitted diseases in London, 1982-1992. *Genitourin Med* 1995;71:286-90.
16. Evans B, Kell P, Bond R, MacRae K. Heterosexual relationships and condom use in the spread of sexually transmitted diseases to women. *Genitourin Med* 1995;71:291-4.
17. Adu-Sarkodie Y, Brook M, Clark S, Bendall R, Kell P, Atia W, Kelsey M. The potential effect on *Neisseria Gonorrhoeae* of the use of clindamycin vaginal cream in the empirical treatment of vaginal discharge. *J Antimicro Chemotherapy* 1995;36:557-60.
18. Williams D, Kell P. Should all women presenting with dysuria be screened for sexually transmitted infections ? *Dilpomate* 1996;1:54-9.
19. Brook M, Kell P, Atia W. Lone circinate balanitis: an underdiagnosed presentation of chlamydia infection in men. *J Eur Acad Dermatol Venereol* 1997;8:34-37.
20. Cassel J, Kell P, Adler M. Pelvic Inflammatory Disease : a review *J Int Ass Phys AIDS Care* 1997;3(10):20-3.
21. Evans B, Kell P, Tasker T, Bond R, MacRae K. Ethnicity, sexual lifestyle and genital infection among women attending a GUM clinic in London. *Sexually Transmitted Infections* 1998;74:45-9.

22. Kell P. New drugs for male erectile dysfunction. *Postgraduate Doctor* 1998;21(5):188-90.
23. Cartledge J, Kell P. Treatment of genital warts. *Postgrad Doctor* 1999;21(2):29-32.
24. Dinsmore W, Gingell C, Hackett G, Kell P, Savage D, Oakes R, FrenztG. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. *BJU* 1999;83:274-9.
25. McCormack W, Dalu Z, Martin D, Hook E, Laisi F, Kell P, Pluck N, Johnson R. Double blind comparison of Trovafloxacin and Doxycycline in the treatment of uncomplicated chlamydial urethritis and cervicitis. *Sex Trans Dis* 1999;26;9 531-6.
26. Coxell A, King M, Mezey G, Kell P. Sexual molestation of men. *Int J STD & AIDS* 2000;11:574-8.
27. Kell P, McMorrow S, Smith A. Syphilis and pregnancy. *CME Bull.* 2000;4(1):9-12.
28. Kell P. The provision of sexual dysfunction services by genito-urinary physicians in the UK in 1999. *Int J STD & AIDS* 2001;12:395-7.
29. Kell P, Curless E. Who should look after patients with sexual dysfunction? Why Genito-Urinary Physicians are ideally placed. *Int J STD & AIDS* 2001;12:351-2.
30. Wright S, Tobin R and Kell P. A novel policy for condom provision in under 16s *STI* 2001;77:287-8.
31. McMorrow S, Kell P. Teenage sexual health: are specific clinics the way forward. *Int J STD&AIDS* 2002;1:4-6.
32. Burns F, Curran B, Tobin R, and P. Kell. Inner City Adolescent Sexual Health—cause for concern. *Int J STD&AIDS* 2002;1:52-4.
33. Kell P. Improving the care of men and women with sexual dysfunction areas for greater collaboration between multi-disciplinary services. *JAPCGT Summer* 2002

34. Rees RW, Ziessen T, Ralph DJ, Kell P, Moncada S, Celtek S. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. *IJIR* 2002;14:1-7.
35. Kell P, Sadeghi-Nejad H, Price D. An Ethical Dilemma: An ethical dilemma: erectile dysfunction in the HIV-Positive patient: to treat or not to treat *Int J STD & AIDS* 2002;13:355-7.
36. Kell P. Cardio-vascular safety of sildenafil. *Int J STD&AIDS* 2002 13;7:439- 442.
37. Kell P, Dean J, Ralph D. Apomorphine SL in the treatment of erectile dysfunction. *BJ Diab Vasc Dis* 2002 2:4;296-301.
38. Nadwani R, Hadjazi L, Kell P. Medical issues in the treatment of sexual dysfunction in HIV sero-positive patients. *Int J STD&AIDS* 2002:9;587-92.
39. Kell P. What's new in oral treatments for ED. *IPMJ* 2002:31;6-10.
40. R Rees, S Minhas, A Minervini, JS Kalsi, JP Peters, PD Kell, DJ Ralph. The management of low-flow Priapism with the immediate insertion of a penile prosthesis *BJU Int* 2002:90;893-7.
41. Smith A, Portsmouth S, Curran B, Warhurst D, Kell P, Saulsbury N
Cobblestone: TV or not TV *STI* 2002:78(3);185-6.
- 42 . Kalsi J, Muneer A, Kell P, Ralph D, Minhas S. Current oral treatments for male erectile dysfunction *Exp Opin Pharm* 2002;3;11:1613-29
43. Kalsi J, Rees R, Hobbs A, Royle M, Kell P, Ralph D, Moncada S. Celtek S. BAY 41-2272 a novel nitric oxide independent soluble guanylyl cyclase activator relaxes human and rabbit corpus cavernosa in vitro. *J Urol* 2003:169;761-6.
44. JS Kalsi, S Minhas, PD Kell, DJ Ralph Oral agents for erectile dysfunction. *Hosp Med* 2003: 64(5); 292-5.

45. Kalsi J, Kell P Ralph D, Minhas S. Erectile dysfunction: new oral treatments Post Grad Doctor 2003;19(2);46-9.
46. Carne C, Foley E, Rowen D, Kell P, Maw R. Variations in clinical practice in GUM clinics in the UK. STI 2003;79:240-2.
47. Rees R, Foxwell N, Ralph D, Kell P, Moncada S, Celtek S. Y-27632 a Rho-Kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003;170:2517-22.
48. Evans B, Kell P, Bond R, MacRae K, Slomka M, Brown D. Predictors of seropositivity to herpes simplex virus Type 2 in women. Int J STD&AIDS 2003;14:30-6.
49. Kalsi J, Kell P, Ralph D, Celtek S. NCX-911, a Novel Nitric Oxide Releasing Inhibitor relaxes rabbit corpus cavernosa in the absence of endogenous Nitric Oxide. IJIR 2004;16:195-200.
50. Kalsi J, Ralph D, Madge D, Kell P, Celtek S. A comparative study of NCX-911, BAY 41-2272 and Sildenafil on the anococcygeus muscle of diabetic rats. IJIR 2004 March 18 (Epub ahead of print).
51. Muneer, A., Celtek, S., Dogan, A., Kell P, Ralph, D.J and Minhas, S. The investigation of cavernosal smooth muscle dysfunction in low flow priapism using an in vitro model. IJIR 2004 April 8 (Epub ahead of print)
52. Kalsi J, Kell P. Update on oral treatments for male erectile dysfunction. J Eur Acad Dermatol Venereol. 2004;18:267-74.
53. Wright S, Kell P, Tobin R. How do clients access their HIV test results from Genitourinary Medicine Services in the UK? A Time For Change ? Int J STD&AIDS 2004;15:584-6

54. Donatucci C, Eardley I, Buvat J, Gittelman M, Kell P, Segerson T, Homering M, Montorsi F. Vardenafil improves erectile function in men with erectile dysfunction Irrespective of disease aetiology and severity. *J Sex Med* 2004;1:301-309
55. Armitage C, Curran B, Wright S, Lenehan K, Kell P. Are we getting the message across ? Trends among young men attending an inner city young people's clinic. *STI* 2004;80:477-9.
56. Eardley I, Mirone V, Montorsi F, Ralph D, Kell P, Warner MR, Zhao Y, Beardsworth A. Open label, multicenter crossover study comparing sildenafil citrate and tadalafil for the treatment of erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. *BJU Int* 2005 96(9):1323-32.
57. Kalsi J, Ralph D, Thomas P, Bellringer J, Minhas S, Kell P, Celtek S. A nitric oxide releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. *J Sex Med* 2005 2(1):53-7.
58. Stockman A, Sharpe L, Smithson H, Tufail A, Kell P, Jeffery G. Viagra affects visual integration time and sensitivity *Current Biology* 2006 16(2):R44-5.
59. Li C, Kayes O, Kell P, Christopher N, Minhas S, Ralph D. Penile suspensory ligament division for penile augmentation: Indications and results *Eur Urology* 2006 49(4):729-733
60. Wright S, Kell P, Tobin R, Breen E. A review of the policy change regarding how patients access their HIV test results at two Genitourinary Medicine Services in central London. *Int J STD&AIDS* 2006;17:753-4.
61. Dinsmore WW, Ralph DJ, Kell P, Wylie KR, Dean J, Novak C, Wylie JS, Wylie MG. Evaluation of the Sexual Assessment Monitor, a diagnostic device used to electronically quantify ejaculatory latency time: findings from three studies. *BJU Int* 2006;98(3):613-8.

62. Kell P, Hvidsten K, Morant S, Harnett J, Bridge S. Factors that predict switching Phosphodiesterase Type 5 Inhibitor medication in the United Kingdom. *BJU Int* . 2007 Apr;99(4):860-3.
63. Willcox J, Huengsborg M, Kell P on behalf of the British Co-operative Clinical Group of the British Association for Sexual Health and HIV. Contraceptive provision in genito-urinary medicine clinics in the United Kingdom *Int J STD and AIDS* 2007;18(2):123-5.
64. E Rutland, E Foley, C O'Mahony, R F Miller, Maw R, Kell P, D Rowen on behalf of the British Co-operative Clinical Group of the British Association for Sexual Health and HIV. How normalised is HIV care in the UK? A survey of current practice and opinion. *Sex Transm Infect*. 2007 Apr;83(2):151-4.
65. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Edwards D. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. *BJU Int*. 2007 Jul;100(1):130-6.
66. Stockman A, Sharpe L, Tufail A, Kell P, Ripamonti C, Jeffery G. The effect of Sildenafil citrate (Viagra) on visual sensitivity. *J Vis* 2007 Jun 8;7(8):4
67. Ferrand R, Abbas A, Kell P. Managing the newly diagnosed HIV-infected individual. *Trends in Urology, Gynaecology and Sexual Health* 2008 13:1;22-26.
68. McMillan A, Kell P, Ward H on behalf of the British Co-operative Clinical Group of the British Association for Sexual Health and HIV. Diagnosing Chlamydia and managing proctitis in men who have sex with men: current UK practice. *STIS* 2008 (in press)
- 69.

RECENT ABSTRACTS:

EADV 2005 W17.5 Penile enhancements-a new local technique Kell P.

EADV 2005 W25.5 Recent advances in sexual dysfunction Kell P.

ESSM 2005 MP-02-091 A comparison of Nesbit's procedure versus plaque incision and grafting for Peyronie's disease Li C-Y, Agarwal V, Kell P, Minhas S, Ralph D.

ESSM 2005 P-01-148 Functional muscarinic receptor subtypes in guinea-pig corporal smooth muscle. Li C-Y, Kumar P, Fry C, Kell P, Ralph D, Minhas S.

ESSM 2005 P-01-151 Neurotransmitters regulating the smooth muscle of seminal vesicle Wang W, Fry C, Kell P, Minhas S, Ralph D, Wu C.

ESSM 2005 P-01-152 Neurotransmitters regulating the smooth muscle of vas deferens Wang W, Fry C, Kell P, Minhas S, Ralph D, Wu C.

ESSM 2005 P-05-254 Correlation of functional outcome and treatment satisfaction in patients with erectile dysfunction and their partners, when treated with Vardenafil Eardley I, Collins O, Ralph D, Kell P.

ESSM 2005 P-07-333 How does treatment of men with ED using a phosphodiesterase type 5 inhibitor improve their life in general? Eardley I, Collins O, Dean J, Kell P, Hackett G, Ralph D, Edwards D.

ESSM 2005 P-07-334 Partners of heterosexual men with erectile dysfunction, treated with Vardenafil, feel them selves to be sexually more desirable. Eardley I,

Collins O, Hackett G, Edwards D, Dean J, Ralph D, Kell P.

ESSM 2005 P-07-340 Differential treatment responses to phosphodiesterase inhibition in a broad population of men, with severe erectile dysfunction, comprised of pre-defined patient subgroups. Ralph D, Collins O, Kell, P, Hackett G, Dean J.

ESSM 2005 P-07-342 The relationship between levels of satisfaction expressed by erectile dysfunction patients treated with a phosphodiesterase type 5 inhibitor, and their partners. Ralph D, Collins O, Dean J, Hackett G, Eardley I, Kell P.

ESSM 2005 P-07-350 The degree of “bother” perceived by patients with erectile dysfunction is subjective and does not predict responsiveness to treatment with a PDE5 inhibitor. Dean J, Collins O, Kell P, Ralph D, Eardley F.

ESSM 2005 PS-02-11 Open label, multicenter, crossover study of Sildenafil citrate and tadalafil for the treatment of erectile dysfunction in patients naïve to phosphodiesterase 5 inhibitor therapy. Eardley I, Montorsi F, Ralph D, Kell P, Zhao Y, Harrison L.M, Beardsworth A, Mirone V.

ESSM 2005 PS-02-018 Efficacy of phosphodiesterase type 5 inhibition in severely affected erectile dysfunction patients with an erectile function domain score of five. Kell P, Collins O, Dean J, Edwards D, Ralph D, Eardley I

ESSM 2005 MP-05-135 The differential effect of ischaemia on nerve mediated and agonist induced contraction in corpus cavernosum Kumar P, Li C, Kell ,P.

ESSM 2005 P-01-147 The effect of temperature on cavernosal smooth muscle contractile function. Kumar P, Li C, Kell ,P.

ESSM 2006 P-05-042 Open pilot studies and a multi-centre, open-label, parallel-group study of the Sexual Assessment Monitor (SAM) in patients with premature ejaculation. Dinsmore, W., Ralph, D., Kell, P., Wyllie, K., Dean, J., Novak, C., Wyllie, J., Wyllie, M.

ESSM 2006 MP-04124 The use of dermal fillers in Andrology. Garaffa, G., Minhas, S. Kell, P. Ralph, D.

ESSM 2006 PP-06291 Evaluation of a Sexual Assessment Monitor (SAM); a diagnostic device for premature ejaculation. Dinsmore, W. Ralph, D. Kell, P Wylie, K. Dean, J. Novak, C. Wyllie, J. Wyllie, M.

B. LETTERS

1. Kell P, Barton S, Catalan J, Hawkins D, Howard L. Letter in reply to "Survey of attitudes to testing for human immunodeficiency virus infection in the ante-natal clinics of West Glamorgan". *Br J Obstet Gynaecol* 1990;97:751-2.

2. Kell P, Boag F, Barton S, Hawkins D. HIV-seropositivity and women. *Int J STD & AIDS* 1991;2:138.

3. Kell P, Barton S. Unravelling the mysteries of vulval ulceration in HIV seropositive women. *Am J Obstet Gynecol* 1991;164(3):935.

4. Kell P, Cracknell M, Barton S, Lawrence A. Testing for HIV antibodies. *BMJ* 1991;302:660-1.

5. Smith D, Kell P, Hills D, Hawkins D, Gazzard B. Domiciliary nebulised pentamidine prophylaxis. *Int J STD & AIDS* 1991;2:215-6.

6. Daniels D, Kell P, Sweeney K, Hulme N, Barton S. Preventing the spread of HIV infection. *BMJ* 1991;302:1399-1400.

7. Evans B, Kell P. Letter in reply to " Increased incidence of cervical cytological abnormalities in women with genital warts". *Genitourin Med* 1992;68:145.

8. Shah P, Smith J, Iatrakis G, Kell P, Barton S, Kitchen V. HIV infection and menstrual abnormalities. *Genitourin Med* 1992;68:425.

9. Kell P. Letter in reply to " Survival time after AIDS in pregnancy". *Br J Obstet Gynaecol* 1993;100:397-8.

10. Desmond N, Morgan H, Kell P. Knowledge about tests for HIV antibodies among pregnant women. *BMJ* 1994;309:877.
11. Kell P, Desmond N. Antenatal attenders and HIV testing. *Int J STD AIDS* 1995;6:299.
12. Robinson A, Kell P. Male partners of women with pelvic infection should be traced. *BMJ* 1995;311:630.
13. Kell P, Dinsmore W. Genito-urinary clinics are an obvious place for treatment of sexual dysfunction *BMJ* 1997;315:429.
14. Burns F, Mercer C, Mercey D, Sadiq T, Curran B, Kell P,. Barriers in HIV testing. A survey of GUM clinic attendees. *Sex Trans Inf* 2004;80:247-8
15. Burns F, Mercer C, Mercey D, Sadiq T, Curran B, Kell P,. Factors that may increase HIV testing in those who decline to test. *STI* 2004;80:249
16. The metabolic syndrome in HIV sero-positive patients. *Int J STD and AIDS* 2007 Jul;18(7):507-8.

C. BOOKS

1. Evans C, Kell P. *Erectile dysfunction*. Health Press 2000 ISBN1-899541-11-X
2. Kell P, Dinsmore W. *Impotence: A Guide for Men of all Ages*. RSM. 2001 ISBN1-85315-402-4 (Commended 2002 BMA Medical Book Competition)
3. Kell P, Griffiths V. *Sexual Health at your fingertips*. Class Press 2003 ISBN1-85959-011-X

D.EDITORIAL BOARD MEMBERSHIP

Sexual Dysfunction RSM press

Journal of Sexual and Reproductive Medicine. Pulsus press

Sexual and Relationship Therapy Carfax Publishing

International Journal STD and AIDS RSM press

MANAGEMENT

1. Master of Business Administration, Open University 2001.
2. Audit lead for HIV/GUM for Mortimer Market/ Archway Sexual Health Clinic 1996-1999
3. Chairman of GUM physicians interest group on sexual dysfunction
4. Consultant in charge of specialist registrar rotation for NE London, covering Mortimer Market, Archway, St Annes and North Middlesex. This entails meeting with each trainee to discuss their individual training needs and liaising between them, their individual academic tutors and the consultants responsible for training at each site. It also requires decisions about each trainees progress through the rotation balancing their training needs with the service requirements of each clinic.
5. Lead Consultant for Contraception Services (2001-3), Camden PCT. This includes Margaret Pyke Centre and 16 community clinics with 120,000 attendances per year
6. Member of Professional Executive Committee Islington PCT.

TEACHING/EDUCATION

1. Regular commitment on lecture course for under-graduate training in GU Medicine.
2. Personal supervision of, and tutorials to, under-graduate students during their clinical attachment to the Archway Sexual Health Clinic.
3. Regular lectures to, and "small group" teaching of, the junior medical staff at the Whittington regarding STDs.
4. Regular lectures to, and "small group" teaching of, the student nurses and midwives at the Whittington regarding HIV disease, particularly ante-natal testing.
5. Regular lectures to, and "small group" teaching of, local GPs regarding sexual health issues.
6. Regular tutorials to trainees in GU Medicine during their attachment to the Archway Clinic.
7. Lecturer on MSc course in psycho-sexual counselling at the Whittington Hospital.
8. Chair of Specialist Advisory Committee which oversees trainees throughout the UK in Genito-urinary Medicine. Special responsibility for the Wales and South Eastern deaneries. Responsible, with other members of SAC, for development of new curriculum and in particular the gynaecology module 1999-2004. Secretary 2004-6. .
9. Member of the JCHMT Committee tasked with assessment of SpRs.
10. Member of Higher Training Committee of FFP. Responsible for developing module of curriculum for SpRs in relation to GUM.
11. Member of PMETB visiting team for deanery visits.
12. MBBS examiner.

SEXUAL DYSFUNCTION EXPERIENCE

1. Past chairman of GU physicians interest group in sexual dysfunction.
2. Treasurer of British Society of Sexual Medicine
3. Member of European Society of Sexual Medicine
4. Member of UK advisory group for Sildenafil, Cialis and Vardenafil
5. Extensive clinical research experience (approx. 10 industry sponsored trials over last 3 years in both male and female dysfunction)
6. Clinical experience - weekly clinic seeing approx 300 new patients per year.
7. Lecturer and course consultant MSc course in psycho-sexual counselling run jointly by Whittington Hospital and the South Bank University.
8. Member of Impotence Society Advisory Committee.
9. Consultant physician Institute of Urology.